{"filing":{"accession_number":"0001279569-26-000889","cik":"0001702123","ticker":"CRDL","company_name":"Cardiol Therapeutics Inc.","form":"6-K","filing_date":"2026-09-16","report_date":"2026-09-16","primary_document":"cardiol6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1702123/000127956926000889/cardiol6k.htm"},"events":[{"id":33769,"run_id":31071,"accession_number":"0001279569-26-000889","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The exhibit announces receipt of over USD $7 million in proceeds from the exercise of outstanding common share purchase warrants, with an additional USD $573,750 in potential proceeds from 425,000 unexercised warrants. While warrant exercises are technically conversions of existing securities rather than new issuances, they result in dilution to existing shareholders through the creation of additional common shares. The proceeds strengthen the company's balance sheet and extend cash runway, which is material to investors assessing the registrant's financial position and ability to fund operations through pivotal Phase III trial data readout.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-16","form":"6-K","submitted_at":null,"items":[{"id":37296,"accession_number":"0001279569-26-000889","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The exhibit announces receipt of over USD $7 million in proceeds from the exercise of outstanding common share purchase warrants, with an additional USD $573,750 in potential proceeds from 425,000 unexercised warrants. While warrant exercises are technically conversions of existing securities rather than new issuances, they result in dilution to existing shareholders through the creation of additional common shares. The proceeds strengthen the company's balance sheet and extend cash runway, which is material to investors assessing the registrant's financial position and ability to fund operations through pivotal Phase III trial data readout.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-16T11:37:50.082131+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37296,"accession_number":"0001279569-26-000889","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The exhibit announces receipt of over USD $7 million in proceeds from the exercise of outstanding common share purchase warrants, with an additional USD $573,750 in potential proceeds from 425,000 unexercised warrants. While warrant exercises are technically conversions of existing securities rather than new issuances, they result in dilution to existing shareholders through the creation of additional common shares. The proceeds strengthen the company's balance sheet and extend cash runway, which is material to investors assessing the registrant's financial position and ability to fund operations through pivotal Phase III trial data readout.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-16T11:37:50.082131+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-16"}]}